Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shifeng Pan

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Journal of Medicinal Chemistry|March 27, 2014
Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacyDean P Phillips, Wenqi Gao, Yang Yang, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of NVP-LDE225, a Potent and Selective Smoothened AntagonistShifeng Pan, Xu Wu, Jiqing Jiang, et al.
Science Translational Medicine|October 1, 2010
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastomaSilvia Buonamici, Juliet Williams, Michael Morrissey, et al.
Chemmedchem|July 3, 2020
A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877Yahu A Liu, Qihui Jin, Qiang Ding, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2013
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974Jun Liu, Shifeng Pan, Mindy H Hsieh, et al.
Journal of Medicinal Chemistry|February 21, 2020
Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133Yahu A Liu, Qihui Jin, Yefen Zou, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Journal of Medicinal Chemistry|March 27, 2014
Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacyDean P Phillips, Wenqi Gao, Yang Yang, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of NVP-LDE225, a Potent and Selective Smoothened AntagonistShifeng Pan, Xu Wu, Jiqing Jiang, et al.
Science Translational Medicine|October 1, 2010
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastomaSilvia Buonamici, Juliet Williams, Michael Morrissey, et al.
Chemmedchem|July 3, 2020
A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877Yahu A Liu, Qihui Jin, Qiang Ding, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2013
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974Jun Liu, Shifeng Pan, Mindy H Hsieh, et al.
Journal of Medicinal Chemistry|February 21, 2020
Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133Yahu A Liu, Qihui Jin, Yefen Zou, et al.
Pageof 7